July 20, 2017 / 8:35 PM / 5 months ago

BRIEF-Amgen says FDA accepts biologics license application for Aimovig

July 20 (Reuters) - Amgen Inc

* FDA accepts biologics license application for Aimovig™ (erenumab)

* Amgen Inc - FDA has set a prescription drug user fee act (PDUFA) target action date of May 17, 2018.

* Amgen Inc - Aimovig will be jointly commercialized in U.S. by Amgen and Novartis. Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below